$IRD

2019 Q1 Form 10-K Financial Statement

#000114036119004539 Filed on March 07, 2019

View on sec.gov

Income Statement

Concept 2019 Q1 2018 Q4 2018 Q3
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.690M $2.240M $1.800M
YoY Change -7.65% 37.42% 14.65%
% of Gross Profit
Research & Development $2.242M $2.730M $2.888M
YoY Change -44.77% -16.26% 9.19%
% of Gross Profit
Depreciation & Amortization $10.00K $10.00K $10.00K
YoY Change 0.0% 0.0% 0.0%
% of Gross Profit
Operating Expenses $3.938M $4.966M $4.684M
YoY Change -33.1% 1.39% 11.01%
Operating Profit -$3.938M -$4.966M -$4.684M
YoY Change -33.1% 1.39% 11.01%
Interest Expense $1.590M $1.850M -$650.0K
YoY Change -53.78% 41.22% -120.44%
% of Operating Profit
Other Income/Expense, Net $1.595M $1.850M -$654.9K
YoY Change -58.15% 41.67% -120.59%
Pretax Income -$2.343M -$3.120M -$5.339M
YoY Change 13.19% -13.09% 414.3%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$2.343M -$3.117M -$5.339M
YoY Change 12.92% -13.25% 414.3%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$2.489M -$4.105M -$8.091M
COMMON SHARES
Basic Shares Outstanding 48.28M 37.52M
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q1 2018 Q4 2018 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $18.02M $14.73M $12.57M
YoY Change -14.92% -45.1% -45.82%
Cash & Equivalents $6.123M $8.744M $4.592M
Short-Term Investments $11.89M $5.980M $7.970M
Other Short-Term Assets $410.2K $555.4K $634.2K
YoY Change -66.65% 8.78% -50.45%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $18.99M $15.90M $13.72M
YoY Change -15.25% -43.49% -43.95%
LONG-TERM ASSETS
Property, Plant & Equipment $99.03K $112.5K $123.5K
YoY Change -9.98% -7.4% 54.35%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $30.00K $30.00K $30.00K
YoY Change 0.0% 0.0% 0.0%
Other Assets
YoY Change
Total Long-Term Assets $432.9K $143.3K $154.3K
YoY Change 209.22% -5.9% 40.24%
TOTAL ASSETS
Total Short-Term Assets $18.99M $15.90M $13.72M
Total Long-Term Assets $432.9K $143.3K $154.3K
Total Assets $19.43M $16.04M $13.87M
YoY Change -13.86% -43.29% -43.58%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $930.0K $550.0K $1.300M
YoY Change -27.34% -38.89% 182.61%
Accrued Expenses $1.430M $2.610M $2.030M
YoY Change -19.21% 11.54% 7.98%
Deferred Revenue $150.0K
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.510M $3.153M $3.330M
YoY Change -17.71% -2.4% 42.31%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $980.0K $2.330M $4.130M
YoY Change -78.41% -71.89% -42.08%
Total Long-Term Liabilities $980.0K $2.330M $4.130M
YoY Change -78.41% -71.89% -42.08%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.510M $3.153M $3.330M
Total Long-Term Liabilities $980.0K $2.330M $4.130M
Total Liabilities $3.485M $5.480M $7.463M
YoY Change -54.02% -52.43% -21.19%
SHAREHOLDERS EQUITY
Retained Earnings -$157.0M -$154.7M -$151.6M
YoY Change 10.24%
Common Stock $173.0M $165.3M $158.0M
YoY Change 5.17%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $15.94M -$1.699M $6.412M
YoY Change
Total Liabilities & Shareholders Equity $19.43M $16.04M $13.87M
YoY Change -13.86% -43.29% -43.58%

Cashflow Statement

Concept 2019 Q1 2018 Q4 2018 Q3
OPERATING ACTIVITIES
Net Income -$2.343M -$3.117M -$5.339M
YoY Change 12.92% -13.25% 414.3%
Depreciation, Depletion And Amortization $10.00K $10.00K $10.00K
YoY Change 0.0% 0.0% 0.0%
Cash From Operating Activities -$4.380M -$4.620M -$4.170M
YoY Change -21.76% 24.86% 20.87%
INVESTING ACTIVITIES
Capital Expenditures -$10.00K $0.00 -$40.00K
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities -$5.880M $2.000M $3.700M
YoY Change -296.0% -166.45% 23.33%
Cash From Investing Activities -$5.895M $2.000M $3.660M
YoY Change -296.67% -165.36% 22.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $7.654M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 7.654M 6.770M 0.000
YoY Change -9.01% -100.0%
NET CHANGE
Cash From Operating Activities -4.380M -4.620M -4.170M
Cash From Investing Activities -5.895M 2.000M 3.660M
Cash From Financing Activities 7.654M 6.770M 0.000
Net Change In Cash -2.622M 4.150M -510.0K
YoY Change 0.79% 510.29% -10.53%
FREE CASH FLOW
Cash From Operating Activities -$4.380M -$4.620M -$4.170M
Capital Expenditures -$10.00K $0.00 -$40.00K
Free Cash Flow -$4.370M -$4.620M -$4.130M
YoY Change -21.94% 26.92% 19.71%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018 dei Amendment Flag
AmendmentFlag
false
CY2018 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2018 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2018 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2018
CY2018 dei Document Period End Date
DocumentPeriodEndDate
2018-12-31
CY2018 dei Document Type
DocumentType
10-K
CY2018 dei Entity Central Index Key
EntityCentralIndexKey
0001228627
CY2019Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
48282995
CY2018 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2018 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2018 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2018Q2 dei Entity Public Float
EntityPublicFloat
44699663
CY2018 dei Entity Registrant Name
EntityRegistrantName
REXAHN PHARMACEUTICALS, INC.
CY2018 dei Entity Shell Company
EntityShellCompany
false
CY2018 dei Entity Small Business
EntitySmallBusiness
true
CY2018 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2018 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2018 dei Trading Symbol
TradingSymbol
rnn
CY2017 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
8052594
CY2018 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-230694
CY2018 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-81376
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2018 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.44
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-56886
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-17836
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
157141021
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
165264215
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
3173
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
3753
CY2017 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1351426
CY2017 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6639421
CY2018 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7428615
CY2017 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
696024
CY2017 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
27390527
CY2018 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
32915377
CY2017Q4 us-gaap Liabilities
Liabilities
11519285
CY2018Q4 us-gaap Liabilities
Liabilities
5480036
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
28287881
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
16042926
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-140318712
CY2018 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13109058
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2017 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10715296
CY2017 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
7594162
CY2017 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15420055
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18838638
CY2017 us-gaap Operating Expenses
OperatingExpenses
17354717
CY2017 us-gaap Payments To Acquire Machinery And Equipment
PaymentsToAcquireMachineryAndEquipment
75168
CY2018 us-gaap Payments To Acquire Machinery And Equipment
PaymentsToAcquireMachineryAndEquipment
39224
CY2017 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
11720000
CY2018Q4 rnn Accumualted Amortization Of Incentive From Lessor
AccumualtedAmortizationOfIncentiveFromLessor
148438
CY2017 rnn Amortization Of Deferred Lease Incentive
AmortizationOfDeferredLeaseIncentive
-12444
CY2018 rnn Amortization Of Deferred Lease Incentive
AmortizationOfDeferredLeaseIncentive
-12443
CY2017 rnn Amortization Of Deferred Research And Development Contribution
AmortizationOfDeferredResearchAndDevelopmentContribution
-75000
CY2018 rnn Amortization Of Deferred Research And Development Contribution
AmortizationOfDeferredResearchAndDevelopmentContribution
-375000
CY2017Q2 rnn Cash Paid In Exchange For Legal Services
CashPaidInExchangeForLegalServices
758732
CY2017Q4 rnn Cash Paid In Exchange For Legal Services
CashPaidInExchangeForLegalServices
559357
CY2018Q4 rnn Cash Paid In Exchange For Legal Services
CashPaidInExchangeForLegalServices
627211
CY2018Q4 rnn Placement Agent Warrants Fair Value At Issuance
PlacementAgentWarrantsFairValueAtIssuance
286906
CY2017Q4 rnn Accumualted Amortization Of Incentive From Lessor
AccumualtedAmortizationOfIncentiveFromLessor
135995
CY2017 rnn Class Of Warrant Or Right Proceeds From Warrants Exercised
ClassOfWarrantOrRightProceedsFromWarrantsExercised
5354093
CY2017Q2 rnn Common Stock Issuance Cost Incurred
CommonStockIssuanceCostIncurred
860002
CY2017Q4 rnn Common Stock Issuance Cost Incurred
CommonStockIssuanceCostIncurred
610534
CY2017 rnn Deferred Lease Expenses
DeferredLeaseExpenses
-10036
CY2018 rnn Deferred Lease Expenses
DeferredLeaseExpenses
-24381
CY2017Q4 rnn Deferred Research And Development Arrangement
DeferredResearchAndDevelopmentArrangement
375000
CY2017Q4 rnn Deferred Tax Assets Book Tax Differences On Assets And Liabilities
DeferredTaxAssetsBookTaxDifferencesOnAssetsAndLiabilities
365000
CY2018Q4 rnn Deferred Tax Assets Book Tax Differences On Assets And Liabilities
DeferredTaxAssetsBookTaxDifferencesOnAssetsAndLiabilities
195000
CY2018 rnn Deferred Tax Assets Valuation Allowance Percentage
DeferredTaxAssetsValuationAllowancePercentage
1.00
CY2018 rnn Defined Contribution Plan Employer Matching Contribution
DefinedContributionPlanEmployerMatchingContribution
1
CY2018 rnn Defined Contribution Plan Maximum Annual Contribution Per Employee Additional Percent On Deferral
DefinedContributionPlanMaximumAnnualContributionPerEmployeeAdditionalPercentOnDeferral
0.5
CY2009Q2 rnn First Achievement Of Marketing Approvals
FirstAchievementOfMarketingApprovals
P30D
CY2017Q4 rnn Incentive From Lessor Net
IncentiveFromLessorNet
18665
CY2018Q4 rnn Incentive From Lessor Net
IncentiveFromLessorNet
6222
CY2018 rnn Investment Warrants Exercised Number
InvestmentWarrantsExercisedNumber
CY2018 rnn Investment Warrants Exercised Weighted Average Exercise Price
InvestmentWarrantsExercisedWeightedAverageExercisePrice
CY2018 rnn Investment Warrants Expired Number
InvestmentWarrantsExpiredNumber
431732
CY2018 rnn Investment Warrants Expired Weighted Average Exercise Price
InvestmentWarrantsExpiredWeightedAverageExercisePrice
5.82
CY2017Q4 rnn Investment Warrants Fair Value
InvestmentWarrantsFairValue
7853635
CY2018Q4 rnn Investment Warrants Fair Value
InvestmentWarrantsFairValue
2307586
CY2017 rnn Investment Warrants Fair Value Assumptions Estimated Dividend
InvestmentWarrantsFairValueAssumptionsEstimatedDividend
CY2018 rnn Investment Warrants Fair Value Assumptions Estimated Dividend
InvestmentWarrantsFairValueAssumptionsEstimatedDividend
CY2017 rnn Investment Warrants Fair Value Assumptions Estimated Future Volatility Rate
InvestmentWarrantsFairValueAssumptionsEstimatedFutureVolatilityRate
1.04
CY2018 rnn Investment Warrants Fair Value Assumptions Estimated Future Volatility Rate
InvestmentWarrantsFairValueAssumptionsEstimatedFutureVolatilityRate
1.05
CY2017 rnn Investment Warrants Fair Value Assumptions Trading Market Prices
InvestmentWarrantsFairValueAssumptionsTradingMarketPrices
2.02
CY2018 rnn Investment Warrants Fair Value Assumptions Trading Market Prices
InvestmentWarrantsFairValueAssumptionsTradingMarketPrices
0.93
CY2017Q2 rnn Investment Warrants Issued Number
InvestmentWarrantsIssuedNumber
1515152
CY2017Q4 rnn Investment Warrants Issued Number
InvestmentWarrantsIssuedNumber
1632654
CY2018 rnn Investment Warrants Issued Number
InvestmentWarrantsIssuedNumber
6115385
CY2018Q4 rnn Investment Warrants Issued Number
InvestmentWarrantsIssuedNumber
5769231
CY2018 rnn Investment Warrants Issued Weighted Average Exercise Price
InvestmentWarrantsIssuedWeightedAverageExercisePrice
1.67
CY2018 rnn Investment Warrants Weighted Average Remaining Contractual Term
InvestmentWarrantsWeightedAverageRemainingContractualTerm
P4Y2M12D
CY2018Q1 rnn Licensing Revenue Agreement
LicensingRevenueAgreement
5000000
CY2018Q1 rnn Licensing Revenue Agreement Percent
LicensingRevenueAgreementPercent
0.5
CY2017Q2 rnn Placement Agent Warrants Fair Value At Issuance
PlacementAgentWarrantsFairValueAtIssuance
434320
CY2017Q4 rnn Placement Agent Warrants Fair Value At Issuance
PlacementAgentWarrantsFairValueAtIssuance
270754
CY2018 rnn Probability Of Entering Into Fundamental Transaction
ProbabilityOfEnteringIntoFundamentalTransaction
0.05
CY2017Q2 rnn Proceeds From Issuance Of Common Stock Allocated To Equity
ProceedsFromIssuanceOfCommonStockAllocatedToEquity
6326835
CY2017Q4 rnn Proceeds From Issuance Of Common Stock Allocated To Equity
ProceedsFromIssuanceOfCommonStockAllocatedToEquity
5639548
CY2017Q2 rnn Proceeds From Issuance Of Common Stock Allocated To Expense
ProceedsFromIssuanceOfCommonStockAllocatedToExpense
333050
CY2017Q4 rnn Proceeds From Issuance Of Common Stock Allocated To Expense
ProceedsFromIssuanceOfCommonStockAllocatedToExpense
219577
CY2017Q2 rnn Proceeds From Issuance Of Common Stock Allocated To Warrant Liabilities
ProceedsFromIssuanceOfCommonStockAllocatedToWarrantLiabilities
3673168
CY2017Q4 rnn Proceeds From Issuance Of Common Stock Allocated To Warrant Liabilities
ProceedsFromIssuanceOfCommonStockAllocatedToWarrantLiabilities
2360459
CY2017Q2 rnn Proceeds From Issuance Of Common Stock Gross
ProceedsFromIssuanceOfCommonStockGross
10000003
CY2017Q4 rnn Proceeds From Issuance Of Common Stock Gross
ProceedsFromIssuanceOfCommonStockGross
8000007
CY2018Q4 rnn Proceeds From Issuance Of Common Stock Gross
ProceedsFromIssuanceOfCommonStockGross
7500000
CY2017Q2 rnn Public Offering Closing Costs
PublicOfferingClosingCosts
1193052
CY2017Q4 rnn Public Offering Closing Costs
PublicOfferingClosingCosts
830111
CY2018Q4 rnn Public Offering Closing Costs
PublicOfferingClosingCosts
896117
CY2009Q2 rnn Research And Developement Agreement One Time Milestone Payment
ResearchAndDevelopementAgreementOneTimeMilestonePayment
1000000
CY2018 rnn Research And Developement Agreement Period
ResearchAndDevelopementAgreementPeriod
P20Y
CY2017 rnn Research And Developement Agreement Period Expense Reduction Amount
ResearchAndDevelopementAgreementPeriodExpenseReductionAmount
75000
CY2018 rnn Research And Developement Agreement Period Expense Reduction Amount
ResearchAndDevelopementAgreementPeriodExpenseReductionAmount
6250
CY2018Q1 rnn Research And Development Arrangement Licensing Revenue
ResearchAndDevelopmentArrangementLicensingRevenue
5000000
CY2018Q1 rnn Research And Development Arrangement Licensing Revenue Percentage
ResearchAndDevelopmentArrangementLicensingRevenuePercentage
0.50
CY2018Q4 rnn Research And Development Estimated Cost To Complete Contracts With Vendors
ResearchAndDevelopmentEstimatedCostToCompleteContractsWithVendors
6340000
CY2017Q4 rnn Warrant Liabilities
WarrantLiabilities
7853635
CY2018Q4 rnn Warrant Liabilities
WarrantLiabilities
2307586
CY2017Q4 rnn Warrants Exercise Price
WarrantsExercisePrice
4.55
CY2018Q4 rnn Warrants Exercise Price
WarrantsExercisePrice
4.55
CY2017 rnn Warrants Issued
WarrantsIssued
6738701
CY2017 rnn Stock Warrants Exercised Shares
StockWarrantsExercisedShares
1652623
CY2017 rnn Stock Warrants Exercised Value
StockWarrantsExercisedValue
13406687
CY2017Q2 rnn Stock Warrants Exercise Price
StockWarrantsExercisePrice
4.00
CY2017Q4 rnn Stock Warrants Exercise Price
StockWarrantsExercisePrice
2.85
CY2018Q4 rnn Stock Warrants Exercise Price
StockWarrantsExercisePrice
1.67
CY2018 rnn Warrants Issued
WarrantsIssued
4841830
CY2017Q2 rnn Warrants Issued Included In Closing Costs
WarrantsIssuedIncludedInClosingCosts
181818
CY2017Q4 rnn Warrants Issued Included In Closing Costs
WarrantsIssuedIncludedInClosingCosts
195919
CY2018Q4 rnn Warrants Issued Included In Closing Costs
WarrantsIssuedIncludedInClosingCosts
346154
CY2017Q2 rnn Warrants Issued Per Share Of Stock Issued In Unit Offering
WarrantsIssuedPerShareOfStockIssuedInUnitOffering
0.5
CY2017Q4 rnn Warrants Issued Per Share Of Stock Issued In Unit Offering
WarrantsIssuedPerShareOfStockIssuedInUnitOffering
0.5
CY2018Q4 rnn Warrants Issued Per Share Of Stock Issued In Unit Offering
WarrantsIssuedPerShareOfStockIssuedInUnitOffering
1
CY2017Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
3233926
CY2018Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
3152550
CY2017Q4 us-gaap Accounts Payable And Accrued Liabilities Current And Noncurrent
AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
3233926
CY2018Q4 us-gaap Accounts Payable And Accrued Liabilities Current And Noncurrent
AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
3152550
CY2017Q4 us-gaap Accounts Payable Trade Current And Noncurrent
AccountsPayableTradeCurrentAndNoncurrent
895638
CY2018Q4 us-gaap Accounts Payable Trade Current And Noncurrent
AccountsPayableTradeCurrentAndNoncurrent
547519
CY2017 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-52012
CY2018 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-39251
CY2017Q4 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
95416
CY2018Q4 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
140637
CY2017Q4 us-gaap Accrued Rent Current And Noncurrent
AccruedRentCurrentAndNoncurrent
38059
CY2018Q4 us-gaap Accrued Rent Current And Noncurrent
AccruedRentCurrentAndNoncurrent
13678
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
711846
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
709117
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1044167
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1228335
CY2017 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1044167
CY2018 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1228335
CY2017Q4 us-gaap Assets
Assets
28287881
CY2018Q4 us-gaap Assets
Assets
16042926
CY2017Q4 us-gaap Assets Current
AssetsCurrent
28135636
CY2018Q4 us-gaap Assets Current
AssetsCurrent
15899668
CY2017Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
17931941
CY2017Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
17931941
CY2017Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
56886
CY2017Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
17988827
CY2017Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
17931941
CY2018Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
5981520
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11578473
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8899154
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8744301
CY2017 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-2679319
CY2018 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-154853
CY2018Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
8494301
CY2018Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.625
CY2017Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
7099609
CY2018Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
12783262
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2018Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
31725114
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37527420
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
31725114
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37527420
CY2017 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-25345267
CY2018 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14329480
CY2018 us-gaap Operating Loss Carryforwards Expiration Date
OperatingLossCarryforwardsExpirationDate
2021-12-31
CY2017Q4 us-gaap Employee Related Liabilities Current And Noncurrent
EmployeeRelatedLiabilitiesCurrentAndNoncurrent
807763
CY2018Q4 us-gaap Employee Related Liabilities Current And Noncurrent
EmployeeRelatedLiabilitiesCurrentAndNoncurrent
682263
CY2018 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-5546049
CY2017Q4 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
1435109
CY2018Q4 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
1782131
CY2017Q4 us-gaap Other Assets Current
OtherAssetsCurrent
510601
CY2018Q4 us-gaap Other Assets Current
OtherAssetsCurrent
555430
CY2017 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-50764
CY2018 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
39050
CY2018 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:10.8pt 0pt 0pt;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 11pt"> <font style="font-size: 11pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 22.5pt 0pt 0pt;"></font><font style="display: inline;"></font><font style="display: inline;font-style:italic;">Concentration of Credit Risk</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 11pt"> <font style="display: inline;">ASC 825, &#x201C;Financial Instruments,&#x201D; requires disclosure of any significant off balance sheet risk and credit risk concentration.&nbsp;&nbsp;The Company does not have significant off</font><font style="display: inline;">&#8209;balance sheet risk or credit concentration</font><font style="display: inline;">.&nbsp;&nbsp;The Company maintains cash and cash equivalents with major financial institutions.&nbsp;&nbsp;From time to time the Company has funds on deposit with commercial banks that exceed federally insured limits.&nbsp;&nbsp;The balances are insured by the Federal Deposit Insurance Corporation up to $250,000. </font><font style="display: inline;">&nbsp;</font><font style="display: inline;">At December 31, 2018, the Company&#x2019;s uninsured cash balance was </font><font style="display: inline;">$8,494,301</font><font style="display: inline;">.</font><font style="display: inline;">&nbsp;</font><font style="display: inline;"> Management does not consider this to be a significant credit risk as the banks are large, established financial institutions.</font> </p> <p><font size="1"> </font></p> </div> </div>
CY2009 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
100000
CY2017 us-gaap Debt Related Commitment Fees And Debt Issuance Costs
DebtRelatedCommitmentFeesAndDebtIssuanceCosts
552627
CY2017Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
56724
CY2018Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
19900
CY2017Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
CY2018Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
35805000
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
41184000
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1458000
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1608000
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
37628000
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
42987000
CY2017 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
123145
CY2018 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
120558
CY2018 us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0.02
CY2018 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
0.03
CY2017 us-gaap Depreciation And Amortization
DepreciationAndAmortization
42358
CY2018 us-gaap Depreciation And Amortization
DepreciationAndAmortization
48211
CY2017Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.91
CY2017Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.04
CY2017Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.04
CY2017Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.12
CY2017 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.92
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.07
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.12
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.17
CY2018Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.09
CY2017Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.91
CY2017Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.03
CY2017Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.04
CY2017Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.12
CY2018 us-gaap Operating Expenses
OperatingExpenses
20537673
CY2018Q2 us-gaap Operating Expenses
OperatingExpenses
5001441
CY2018Q3 us-gaap Operating Expenses
OperatingExpenses
4683907
CY2018Q4 us-gaap Operating Expenses
OperatingExpenses
4966470
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3953241
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
-17354717
CY2017Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-4283925
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4219322
CY2017Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-4898229
CY2017Q4 us-gaap Incentive From Lessor
IncentiveFromLessor
154660
CY2018Q4 us-gaap Incentive From Lessor
IncentiveFromLessor
154660
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-25294503
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-14368530
CY2017 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
CY2017 us-gaap Investment Income Interest
InvestmentIncomeInterest
207003
CY2018 us-gaap Investment Income Interest
InvestmentIncomeInterest
254344
CY2017 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
31200
CY2018 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
22650
CY2017Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
7853635
CY2018Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
2307586
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-5885855
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
-20537673
CY2018Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-5001441
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4683907
CY2018Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-4966470
CY2017 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-7939786
CY2017Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5230981
CY2017Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3181250
CY2017Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1305766
CY2018Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3810982
CY2018 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
6169143
CY2018Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1163173
CY2018Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-654912
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
210548
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
176080
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
34468
CY2017Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
127877000
CY2018Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
147086000
CY2018 us-gaap Nature Of Operations
NatureOfOperations
<div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt 0pt 0pt 21.6pt;text-indent:-21.6pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-weight:bold;font-family:Times New Roman;font-size: 11pt"> <font style="display: inline;">1.</font><font style="display: inline;;font-size: 11pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;">Operations and Organization</font> </p> <p style="margin:10.8pt 0pt 0pt 23.75pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 11pt"> <font style="display: inline;">Rexahn Pharmaceuticals, Inc. (the &#x201C;Company&#x201D;), a Delaware corporation, is a biopharmaceutical company whose principal operations are the development of innovative treatments for cancer.&nbsp;&nbsp;The Company had an accumulated deficit of </font><font style="display: inline;">$</font><font style="display: inline;color:#000000;">154,687,242</font><font style="display: inline;"> at December 31, 2018 and anticipates incurring losses through fiscal year 2019 and beyond.&nbsp;&nbsp;The Company has not yet generated commercial revenues and has funded its operati</font><font style="display: inline;">ons</font><font style="display: inline;"> to date through the sale of shares of its common stock</font><font style="display: inline;"> and warrants</font><font style="display: inline;">, exercises of stock warrants, interest income from cash, cash equivalents and marketable securities, and proceeds from reimbursed research and development costs.&nbsp;&nbsp;The Company believes that its cash, cash equivalents</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">and marketable securities, including the proceeds from its underwritten public offering in January 2019 as described in Note 18, will be sufficient to cover its cash flow requirements for its current activities for at least for the next 12 months from the date these financial statements were issued.&nbsp;&nbsp;Management believes it has the capability of managing the Company&#x2019;s operations within existing cash available by focusing on select research and development activities, selecting projects in conjunction with potential financings and milestones, and efficiently managing its general and administrative affairs.</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 11pt"> <font style="display: inline;font-weight:bold;background-color:yellow;">&#xFEFF;</font> </p> <p><font size="1"> </font></p> </div> </div>
CY2017 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
22113514
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6772789
CY2017 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-9372778
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
11910996
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-21611024
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-25294503
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
947056
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-1038072
CY2017Q4 us-gaap Net Income Loss
NetIncomeLoss
-3592463
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-2074873
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-14368530
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-3838268
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-5338819
CY2018Q4 us-gaap Net Income Loss
NetIncomeLoss
-3116570
CY2017Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-17657783
CY2018Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1849900
CY2017Q1 us-gaap Operating Expenses
OperatingExpenses
3953241
CY2017Q2 us-gaap Operating Expenses
OperatingExpenses
4283925
CY2017Q3 us-gaap Operating Expenses
OperatingExpenses
4219322
CY2017Q4 us-gaap Operating Expenses
OperatingExpenses
4898229
CY2018Q1 us-gaap Operating Expenses
OperatingExpenses
5885855
CY2017 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-50764
CY2018 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
39050
CY2018 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
368750
CY2018Q1 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
368750
CY2017Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
793940
CY2018Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
618417
CY2018 us-gaap Other Tax Expense Benefit
OtherTaxExpenseBenefit
0
CY2018 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
100000
CY2017 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
21017610
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1304541
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1173847
CY2018 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:10.8pt 0pt 0pt;text-indent:36pt;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 11pt"> <font style="display: inline;font-style:italic;">Reclassification</font> </p> <p style="margin:10.8pt 0pt 0pt 36pt;border-top:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 11pt"> <font style="display: inline;">Certain amounts in the prior year&#x2019;s financial statements have been reclassified to conform to the current year presentation with no material impact on the financial statements.</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 11pt"> <font style="display: inline;;font-size: 11pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;"></font> </p> <p><font size="1"> </font></p> </div> </div>
CY2017 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
16681921
CY2018 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
6872789
CY2018 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
11950220
CY2017 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
77500
CY2017 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
5354093
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
833306
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
821590
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
121460
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
112473
CY2003 us-gaap Research And Development Arrangement Contract To Perform For Others Compensation Earned
ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
1500000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-154687242
CY2017Q1 us-gaap Revenues
Revenues
CY2017 us-gaap Revenues
Revenues
CY2017Q2 us-gaap Revenues
Revenues
CY2017Q3 us-gaap Revenues
Revenues
CY2017Q4 us-gaap Revenues
Revenues
CY2018Q1 us-gaap Revenues
Revenues
CY2018 us-gaap Revenues
Revenues
CY2018Q2 us-gaap Revenues
Revenues
CY2018Q3 us-gaap Revenues
Revenues
CY2018Q4 us-gaap Revenues
Revenues
CY2018 us-gaap Stock Issued During Period Shares Restricted Stock Award Gross
StockIssuedDuringPeriodSharesRestrictedStockAwardGross
18075
CY2017 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
25000
CY2017 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
31200
CY2018 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
22650
CY2017 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
10495847
CY2018 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
6872789
CY2017 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
77500
CY2017Q4 us-gaap Security Deposit
SecurityDeposit
30785
CY2018Q4 us-gaap Security Deposit
SecurityDeposit
30785
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
1044167
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
1228335
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
53883
CY2017Q2 us-gaap Share Price
SharePrice
3.30
CY2017Q4 us-gaap Share Price
SharePrice
2.45
CY2018Q4 us-gaap Share Price
SharePrice
1.30
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
17058462
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
16768596
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
10562890
CY2017Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.1
CY2017 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
15000
CY2018 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
15000
CY2017Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
3030304
CY2017Q4 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
3265309
CY2018Q4 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
5769231
CY2018 us-gaap Use Of Estimates
UseOfEstimates
<div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:10.8pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 11pt"> <font style="font-size: 11pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;"></font><font style="display: inline;font-style:italic;">Use of Estimates</font><font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 11pt"> <font style="display: inline;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.&nbsp;&nbsp;These estimates are based on management&#x2019;s best knowledge of current events and actions the Company may undertake in the future.&nbsp;&nbsp;Actual results may ultimately differ from these estimates.&nbsp;&nbsp;These estimates are reviewed periodically and as adjustments become necessary, they are reported in earnings in the period in which they become available.</font> </p> <p><font size="1"> </font></p> </div> </div>

Files In Submission

Name View Source Status
0001140361-19-004539-index-headers.html Edgar Link pending
0001140361-19-004539-index.html Edgar Link pending
0001140361-19-004539.txt Edgar Link pending
0001140361-19-004539-xbrl.zip Edgar Link pending
ex10_7.htm Edgar Link pending
ex23_1.htm Edgar Link pending
ex24_1.htm Edgar Link pending
ex31_1.htm Edgar Link pending
ex32_1.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
form10k.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rnn-20181231.xml Edgar Link completed
rnn-20181231.xsd Edgar Link pending
rnn-20181231_cal.xml Edgar Link unprocessable
rnn-20181231_def.xml Edgar Link unprocessable
rnn-20181231_lab.xml Edgar Link unprocessable
rnn-20181231_pre.xml Edgar Link unprocessable
Show.js Edgar Link pending